For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > REGULATORY
REGULATORY
- Cabinet Presents Reform of Drug Discovery Support Network Including Use of CROs, Transfer of Drug Makers’ Employees
April 3, 2017
- Avigan Might Be Used for Pandemic Influenza if Existing NA Inhibitors Are Ineffective: Expert Council
April 3, 2017
- CEFP Kicks Off Discussions on Economic and Fiscal Policy Blueprint for 2017
March 31, 2017
- Members of New Counterfeits Panel Call for Eliminating Cash-and-Carry Dealers
March 31, 2017
- Clinical Research Bill Likely to Clear Diet Early April
March 31, 2017
- MHLW Approves Ninlaro, Intuniv, Other Drugs
March 31, 2017
- MHLW to Set up New Council to Discuss Safety Measures for Pharmacotherapy in the Elderly
March 31, 2017
- Drug Price Survey Sheets to Be Distributed with No Prefectural Govts In-Between: Chuikyo
March 30, 2017
- AMED Racks Up 1st Out-Licensing Cases in Drug Discovery Support Initiative
March 30, 2017
- Chuikyo Gives Ex-Post Nod to Opdivo’s Optimal Use Guidelines for Head-and-Neck Cancer
March 30, 2017
- CDISC-Based Electronic Submissions for 19 Products Since October: PMDA
March 29, 2017
- MHLW Seeks Cooperation for Sovaldi’s PMS for Genotype 3-6 Use
March 28, 2017
- Promotion Plan for Cancer Genomics Due Out This Summer
March 28, 2017
- MHLW Issues Optimal Use Guidelines for Opdivo Following Approval of Add’l Indication for Head and Neck Cancer
March 28, 2017
- MHLW Orders Label Revisions for Lamictal, Zione
March 27, 2017
- Orphan Designation Granted for Olaparib, 3 Other Drugs
March 27, 2017
- Cabinet OKs PMDA’s Review Fee Raise from April 1
March 27, 2017
- MHLW OKs Sovaldi for Genotypes 3-6, Opdivo for Head and Neck Cancer
March 27, 2017
- MHLW Poised to Review System Designs to Prevent Counterfeits: Minister
March 24, 2017
- No Extra Fees Will Be Charged for Add’l Survey Items for MID-NET’s PMS Use: MHLW Working Group
March 23, 2017
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…